Commission Implementing Regulation (EU) 2023/1757 of 11 September 2023 amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances bensulfuron, chlormequat, chlorotoluron, clomazone, daminozide, deltamethrin, eugenol, fludioxonil, flufenacet, flumetralin, fosthiazate, geraniol, MCPA, MCPB, propaquizafop, prosulfocarb, quizalofop-P-ethyl, quizalofop-P-tefuryl, sodium 5-nitroguaiacolate, sodium o-nitrophenolate, sodium p-nitrophenolate, sulfuryl fluoride, tebufenpyrad, thymol, and tritosulfuron (Text with EEA relevance)

Implementing Regulation (EU) 2023/1757 · Regulation · 3 articles

Data as of 2026-07-04 · Compiled from an official source version. Later amendments or repeals may not be reflected; the official text prevails. · Read the official text ↗

Article 1

The Annex to Implementing Regulation (EU) No 540/2011 is amended in accordance with the Annex to this Regulation.

Article 2

This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union .

Supplementary provisions

ANNEXSupplementary provisions

ANNEX The Annex to Implementing Regulation (EU) No 540/2011 is amended as follows: 1. Part A is amended as follows: (1) in the sixth column, expiration of approval, of row 40, Deltamethrin, the date is replaced by ‘15 August 2026’; (2) in the sixth column, expiration of approval, of row 65, Flufenacet, the date is replaced by ‘15 June 2025’; (3) in the sixth column, expiration of approval, of row 69, Fosthiazate, the date is replaced by ‘31 January 2027’; (4) in the sixth column, expiration of approval, of row 102, Chlorotoluron, the date is replaced by ‘15 August 2026’; (5) in the sixth column, expiration of approval, of row 104, Daminozide, the date is replaced by ‘15 September 2025’; (6) in the sixth column, expiration of approval, of row 107, MCPA, the date is replaced by ‘15 August 2026’; (7) in the sixth column, expiration of approval, of row 108, MCPB, the date is replaced by ‘15 August 2026’; (8) in the sixth column, expiration of approval, of row 160, Prosulfocarb, the date is replaced by ‘31 January 2027’; (9) in the sixth column, expiration of approval, of row 161, Fludioxonil, the date is replaced by ‘15 June 2025’; (10) in the sixth column, expiration of approval, of row 162, Clomazone, the date is replaced by ‘15 June 2025’; (11) in the sixth column, expiration of approval, of row 186, Tritosulfuron, the date is replaced by ‘15 July 2025’; (12) in the sixth column, expiration of approval, of row 271, Bensulfuron, the date is replaced by ‘15 August 2026’; (13) in the sixth column, expiration of approval, of row 272, Sodium 5-nitroguaiacolate, the date is replaced by ‘31 January 2027’; (14) in the sixth column, expiration of approval, of row 273, Sodium o-nitrophenolate, the date is replaced by ‘31 January 2027’; (15) in the sixth column, expiration of approval, of row 274, Sodium p-nitrophenolate, the date is replaced by ‘31 January 2027’; (16) in the sixth column, expiration of approval, of row 275, Tebufenpyrad, the date is replaced by ‘31 January 2027’; (17) in the sixth column, expiration of approval, of row 276, Chlormequat, the date is replaced by ‘28 February 2027’; (18) in the sixth column, expiration of approval, of row 278, Propaquizafop, the date is replaced by ‘28 February 2027’; (19) in the sixth column, expiration of approval, of row 279, Quizalofop-P-ethyl and Quizalofop-P-tefuryl, the date is replaced by ‘28 February 2027’; (20) in the sixth column, expiration of approval, of row 307, Sulfuryl fluoride, the date is replaced by ‘31 January 2027’. 2. Part B is amended as follows: (1) in the sixth column, expiration of approval, of row 45, Eugenol, the date is replaced by ‘30 April 2026’; (2) in the sixth column, expiration of approval, of row 46, Geraniol, the date is replaced by ‘30 April 2026’; (3) in the sixth column, expiration of approval, of row 47, Thymol, the date is replaced by ‘30 April 2026’; 3. Part E is amended as follows: in the sixth column, expiration of approval, of row 1, Flumetralin, the date is replaced by ‘ 11 May 2026 ’.

Other acts of the same type

Source: EUR-Lex (Publications Office of the EU), © European Union, reuse permitted under Commission Decision 2011/833/EU.

What to look at next

Browse all EU Legal ActsEvery instrument by type and year, full text free to read section by sectionEuropean Union legislation EU Legal Acts by type and yearGrouped by instrument type and year of enactment, so you can find others of the same kindBrowse by type and year European Union: what this database coversWhich datasets are here, which official source they come from, and how current they areEuropean Union overview